Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease

American Journal of Clinical Pathology

Volumn 126, Issue 5, 2006, Pages 789-797

  Wang, Sa A ^a   Galili, Naomi ^a   Cerny, Jan ^a   Sechman, Eric ^a   Chen, Su Sin ^b   Loew, Jerome ^c   Liu, Qin ^a   Fadare, Oluwole ^d   Hasserjian, Robert ^e   Jones, Dan ^b   Qawi, Huma ^a   Woda, Bruce ^a   Raza, Azra ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d WILFORD HALL MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chronic myelomonocytic leukemia; Evolution; Myelodysplastic syndrome; Overall survival

Indexed keywords

FLT3 LIGAND; JANUS KINASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MYELODYSPLASIA; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SURVIVAL TIME;

EID: 33750718814     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/FU04P779U310R3EE     Document Type: Article

References (38)

1. San Miguel JF, Sanz GF, Vallespi T, et al. Myelodysplastic syndromes. Crit Rev Oncol Hematol. 1996;23:57-93.
2. Bennett JM, Kouides PA, Forman SJ. The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002). Int J Hematol. 2002;76(suppl 2):228-238.
3. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol. 1994;87:746-754.
4. Everson MP, Brown CB, Lilly MB. Interleukin-6 and granulocyte-macrophage colony-stimulating factor are candidate growth factors for chronic myelomonocytic leukemia cells. Blood. 1989;74:1472-1476.
5. Ramshaw HS, Bardy PG, Lee MA, et al. Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo. Exp Hematol. 2002;30:1124-1131.
6. Bruming RD, Matutes E, Harris NL, et al. Acute myeloid leukaemia. In: Jaffe ES, Harris NL, Stein H, et al, ed. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:77-80. World Health Organization Classification of Tumours.
7. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol. 2000;72:131-133.
8. Neuwirtova R, Mocikova K, Musilova J, et al. Mixed myelodysplastic and myeloproliferative syndromes. Leuk Res. 1996;20:717-726.
9. Hasegawa Y, Sakai N, Toyama M, et al. Chronic myelomonocytic leukemia transformed from refractory anemia with ring sideroblasts with a rare abnormal chromosome, inv(12). Rinsho Ketsueki. 1990;31:75-79.
10. Verhoef GE, Demuynck H, Zachee P, et al. Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two [letter]? Leukemia. 1994;8:714-715.
11. Del Canizo MC, Brufau A, Mota A, et al. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders. Haematologica. 1998;83:3-7.
12. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
13. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 1998;83:358-368.
14. Mitelman F, ed. ISCN 1995: An International System for Human Cytogenetic Nomenclature 1995. Basel, Switzerland: S Karger; 1995.
15. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207-1209.
16. Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100:2387-2392.
17. Nosslinger T, Reisner R, Gruner H, et al. Dysplastic versus proliferative CMML: a retrospective analysis of 91 patients from a single institution. Leuk Res. 2001;25:741-747.
18. Onida F, Beran M. Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep. 2004;33:218-226.
19. Voglova J, Chrobak L, Neuwirtova R, et al. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia: distinct subgroups or two stages of the same disease? Leuk Res. 2001;25:493-499.
20. Gonzalez-Medina I, Bueno J, Torrequebrada A, et al. Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative: prognostic implications in a series of a single center. Leuk Res. 2002;26:821-824.
21. Germing U, Gattermann N, Minning H, et al. Problems in the classification of CMML: dysplastic versus proliferative type. Leuk Res. 1998;22:871-878.
22. Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma. 2004;45:1311-1318.
23. Rigolin GM, Cuneo A, Roberti MG, et al. Myelodysplastic syndromes with monocytic component: hematologic and cytogenetic characterization. Haematologica. 1997;82:25-30.
24. Cunningham I, MacCallum SJ, Nicholls MD, et al. The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. Br J Haematol. 1995;90:602-606.
25. Beran M, Shen Y, Onida F, et al. Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leuk Lymphoma. 2006;47:417-423.
26. Chen YC, Chou JM, Ketterling RP, et al. Histologic and immunohistochemical study of bone marrow monocytic nodules in 21 cases with myelodysplasia. Am J Clin Pathol. 2003;120:874-881.
27. Chen YC, Chou JM, Letendre L, et al. Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: retrospective analysis of 21 cases. Am J Hematol. 2005;79:329-331.
28. Rombouts WJ, Lowenberg B, van Putten WL, et al. Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene. Leukemia. 2001;15:1046-1053.
29. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-1542.
30. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [correction appears in Lancet. 2005;366:122]. Lancet. 2005;365:1054-1061.
31. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
32. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
33. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.
34. Johan MF, Goodeve AC, Bowen DT, et al. JAK2 V617F mutation is uncommon in chronic myelomonocytic leukaemia [letter]. Br J Haematol. 2005;130:968.
35. Padua RA, Carter G, Hughes D, et al. RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. Leukemia. 1988;2:503-510.
36. Darley RL, Burnett AK. Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors. Exp Hematol. 1999;27:1599-1608.
37. Greenberg P. In vitro marrow culture studies in the myelodysplastic syndromes. Semin Oncol. 1992;19:34-46.
38. Geissler K, Ohler L, Fodinger M, et al. Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells. J Exp Med. 1996;184:1377-1384.